LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-?B/p50 and SLUG

We provide evidence that NOAT113026 inhibits renal cancer proliferative and mobility potential by blocking NF-?B/p50 and SLUG expression, which consequently inhibiting the production of oncogenic chemokines and metastasis-promoting genes. Our findings manifest that NOAT113026 may become a critical and feasible target for RCC treatment because of its anti-proliferative and anti-metastatic properties and emerge as an important biomarker for the detection of overall survival and disease-free survival. Overall design: We reported a long non-coding RNA (lncRNA), NONHSAT 113026 (NOAT113026), that may play an important role in the pathogenesis of RCC. The expression level of NOAT113026 was estimated by qPCR from 76 pairs of RCC and NT samples. The correlation of NOAT113026 to clinical data of RCC patients was analyzed. NOAT113026 was overexpressed in 786-O and ACHN cell lines by lentivirus-mediated technology, and the oncological behavioral changes of RCC cells were observed, as well as, tumorigenicity in experimental nude mice. Compared to the adjacent tissues, NOAT113026 was obviously downregulated in RCC. Survival analysis showed that the lower the expression level of NOAT113026, the shorter the disease-free survival and overall survival in RCC. Overexpression of NOAT113026 can decrease the ability of cell migration, invasion, proliferation, and colony formation by regulating NF-?B/p50 and SLUG through a mechanism that involves lncRNA-mRNA interactions.